Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1996 Jul 1;184(1):51–60. doi: 10.1084/jem.184.1.51

Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes [published erratum appears in J Exp Med 1996 Nov 1;184(5):2075]

PMCID: PMC2192662  PMID: 8691149

Abstract

We have developed a functional assay to study the inflammatory capacity of plasma collected from patients with severe gram-negative septic shock. In this assay, elutriation-purified, cryo-preserved human monocytes from one healthy donor are combined with plasma from patients with severe persistent septic shock for 5 h. Subsequently, the plasma is removed, medium added, and procoagulant activity (PCA) and secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) measured after 18-h incubation. Plasma from 10 patients (6 died) infected with Neisseria meningitidis previously shown to contain high levels of native lipopolysaccharide (LPS) (median 2,700 pg/ml), TNF- alpha, IL-6, IL-8, and complement activation products, had a low net spontaneous inflammatory capacity on the monocytes. The median levels of PCA, TNF-alpha, and IL-6 were 5, 0, and 4%, respectively, of the monocyte activities induced by normal plasma boosted with purified N. meningitidis (Nm)-LPS (2,500 pg/ml; net LPS-boosted capacity, 100%). The levels of PCA, TNF-alpha, and IL-6 obtained with plasma from shock patients were not different from those induced by plasma from 10 meningococcal patients without shock or with plasma from healthy persons. Boosting shock plasma with 2,500 pg/ml Nm-LPS had little effect on the monocyte activities since the median values of PCA, TNF- alpha, and IL-6 revealed a minimal increase from 5, 0, and 4% to 9, 2, and 6%, respectively. The shock plasmas revealed a strong LPS- inhibitory capacity that was largely absent in plasmas from 10 meningococcal patients without shock since the median levels of PCA, TNF-alpha, and IL-6 increased from 5, 0, and 0% to 135, 51, and 73%, respectively, after boosting with 2,500 pg/ml Nm-LPS. The LPS- inhibitory capacity was closely associated with the levels of IL-10. The median levels of IL-10 were 19,000 pg/ml in nine shock patients vs. 22 pg/ml in nine nonshock patients with systemic meningococcal disease. Removal of native IL-10 by immunoprecipitation restored the capacity of plasmas to induce monocyte activation either by native LPS or by boosting with Nm-LPS. IL-4 and TGF-beta were not detected in shock plasmas. In 24 patients with detectable meningococcal LPS ( > 10 pg/ml, 0.1 endotoxin units/ml), the levels of IL-10 were correlated to the levels of LPS (r = 0.79, P < 0.001). IL-10 declined from initiation of antibiotic therapy and paralleled the levels of native LPS. Decreasing levels of IL-10 in serially collected shock plasmas were directly related to increasing monocyte responsiveness after Nm-LPS boosting. These results suggest that IL-10 plays a major role in containing activation of monocytes and possibly other LPS-responsive cells during overwhelming meningococcemia.

Full Text

The Full Text of this article is available as a PDF (986.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen P., Kierulf P., Elde A. T., Godal H. C. The antithrombin and antiheparin effects of crude and highly purified alpha 1-acid glycoprotein. Thromb Res. 1980 Aug 1;19(3):401–408. doi: 10.1016/0049-3848(80)90268-6. [DOI] [PubMed] [Google Scholar]
  2. Bogdan C., Paik J., Vodovotz Y., Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem. 1992 Nov 15;267(32):23301–23308. [PubMed] [Google Scholar]
  3. Brandtzaeg P., Bryn K., Kierulf P., Ovstebø R., Namork E., Aase B., Jantzen E. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest. 1992 Mar;89(3):816–823. doi: 10.1172/JCI115660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brandtzaeg P., Halstensen A., Kierulf P., Espevik T., Waage A. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Pathog. 1992 Dec;13(6):423–431. doi: 10.1016/0882-4010(92)90010-l. [DOI] [PubMed] [Google Scholar]
  5. Brandtzaeg P., Høgåsen K., Kierulf P., Mollnes T. E. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis. 1996 Mar;173(3):647–655. doi: 10.1093/infdis/173.3.647. [DOI] [PubMed] [Google Scholar]
  6. Brandtzaeg P., Joø G. B., Brusletto B., Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res. 1990 Jan 15;57(2):271–278. doi: 10.1016/0049-3848(90)90326-8. [DOI] [PubMed] [Google Scholar]
  7. Brandtzaeg P., Kierulf P., Gaustad P., Skulberg A., Bruun J. N., Halvorsen S., Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989 Feb;159(2):195–204. doi: 10.1093/infdis/159.2.195. [DOI] [PubMed] [Google Scholar]
  8. Brandtzaeg P., Mollnes T. E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis. 1989 Jul;160(1):58–65. doi: 10.1093/infdis/160.1.58. [DOI] [PubMed] [Google Scholar]
  9. Brandtzaeg P., Sandset P. M., Joø G. B., Ovstebø R., Abildgaard U., Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res. 1989 Aug 15;55(4):459–470. doi: 10.1016/0049-3848(89)90054-6. [DOI] [PubMed] [Google Scholar]
  10. Burrell R. Human responses to bacterial endotoxin. Circ Shock. 1994 Jul;43(3):137–153. [PubMed] [Google Scholar]
  11. Derkx B., Marchant A., Goldman M., Bijlmer R., van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis. 1995 Jan;171(1):229–232. doi: 10.1093/infdis/171.1.229. [DOI] [PubMed] [Google Scholar]
  12. Flegel W. A., Baumstark M. W., Weinstock C., Berg A., Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun. 1993 Dec;61(12):5140–5146. doi: 10.1128/iai.61.12.5140-5146.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Girardin E., Grau G. E., Dayer J. M., Roux-Lombard P., Lambert P. H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988 Aug 18;319(7):397–400. doi: 10.1056/NEJM198808183190703. [DOI] [PubMed] [Google Scholar]
  14. Granowitz E. V., Porat R., Mier J. W., Orencole S. F., Kaplanski G., Lynch E. A., Ye K., Vannier E., Wolff S. M., Dinarello C. A. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 1993 Aug 1;151(3):1637–1645. [PubMed] [Google Scholar]
  15. Gårdlund B., Sjölin J., Nilsson A., Roll M., Wickerts C. J., Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis. 1995 Jul;172(1):296–301. doi: 10.1093/infdis/172.1.296. [DOI] [PubMed] [Google Scholar]
  16. Gérard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993 Feb 1;177(2):547–550. doi: 10.1084/jem.177.2.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. HJORT P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin; convertin, accelerin, prothrombinase. Scand J Clin Lab Invest. 1957;9 (Suppl 27):1–183. [PubMed] [Google Scholar]
  18. Halstensen A., Ceska M., Brandtzaeg P., Redl H., Naess A., Waage A. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis. 1993 Feb;167(2):471–475. doi: 10.1093/infdis/167.2.471. [DOI] [PubMed] [Google Scholar]
  19. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993 Apr 1;177(4):1205–1208. doi: 10.1084/jem.177.4.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Høiby E. A., Bjune G., Frøholm L. O., Eng J., Halstensen A., Rosenqvist E., Rønnild E., Wedege E. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann. 1991 Dec;14(2):107–123. [PubMed] [Google Scholar]
  21. Jungi T. W., Brcic M., Eperon S., Albrecht S. Transforming growth factor-beta and interleukin-10, but not interleukin-4, down-regulate procoagulant activity and tissue factor expression in human monocyte-derived macrophages. Thromb Res. 1994 Dec 1;76(5):463–474. doi: 10.1016/0049-3848(95)90178-i. [DOI] [PubMed] [Google Scholar]
  22. Lehmann A. K., Halstensen A., Sørnes S., Røkke O., Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun. 1995 Jun;63(6):2109–2112. doi: 10.1128/iai.63.6.2109-2112.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Marchant A., Bruyns C., Vandenabeele P., Abramowicz D., Gérard C., Delvaux A., Ghezzi P., Velu T., Goldman M. The protective role of interleukin-10 in endotoxin shock. Prog Clin Biol Res. 1994;388:417–423. [PubMed] [Google Scholar]
  24. Marchant A., Devière J., Byl B., De Groote D., Vincent J. L., Goldman M. Interleukin-10 production during septicaemia. Lancet. 1994 Mar 19;343(8899):707–708. doi: 10.1016/s0140-6736(94)91584-9. [DOI] [PubMed] [Google Scholar]
  25. McCarthy P. L. Down-regulation of cytokine action. Baillieres Clin Haematol. 1994 Mar;7(1):153–177. doi: 10.1016/s0950-3536(05)80011-3. [DOI] [PubMed] [Google Scholar]
  26. Munoz C., Carlet J., Fitting C., Misset B., Blériot J. P., Cavaillon J. M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991 Nov;88(5):1747–1754. doi: 10.1172/JCI115493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Munoz C., Misset B., Fitting C., Blériot J. P., Carlet J., Cavaillon J. M. Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol. 1991 Sep;21(9):2177–2184. doi: 10.1002/eji.1830210928. [DOI] [PubMed] [Google Scholar]
  28. Osnes L. T., Westvik A. B., Kierulf P. Procoagulant and profibrinolytic activities of cryopreserved human monocytes. Thromb Res. 1994 Nov 15;76(4):373–383. doi: 10.1016/0049-3848(94)90166-x. [DOI] [PubMed] [Google Scholar]
  29. Osterud B., Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 1983 Feb 28;49(1):5–7. [PubMed] [Google Scholar]
  30. Ramani M., Ollivier V., Khechai F., Vu T., Ternisien C., Bridey F., de Prost D. Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes. FEBS Lett. 1993 Nov 8;334(1):114–116. doi: 10.1016/0014-5793(93)81693-t. [DOI] [PubMed] [Google Scholar]
  31. Ramani M., Ollivier V., Ternisien C., Vu T., Elbim C., Hakim J., de Prost D. Interleukin 4 prevents the induction of tissue factor mRNA in human monocytes in response to LPS or PMA stimulation. Br J Haematol. 1993 Nov;85(3):462–468. doi: 10.1111/j.1365-2141.1993.tb03333.x. [DOI] [PubMed] [Google Scholar]
  32. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  34. Waring P. M., Waring L. J., Metcalf D. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis. 1994 Nov;170(5):1224–1228. doi: 10.1093/infdis/170.5.1224. [DOI] [PubMed] [Google Scholar]
  35. Wong H. L., Lotze M. T., Wahl L. M., Wahl S. M. Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J Immunol. 1992 Apr 1;148(7):2118–2125. [PubMed] [Google Scholar]
  36. Wurfel M. M., Kunitake S. T., Lichenstein H., Kane J. P., Wright S. D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994 Sep 1;180(3):1025–1035. doi: 10.1084/jem.180.3.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. van Deuren M., van der Ven-Jongekrijg J., Bartelink A. K., van Dalen R., Sauerwein R. W., van der Meer J. W. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis. 1995 Aug;172(2):433–439. doi: 10.1093/infdis/172.2.433. [DOI] [PubMed] [Google Scholar]
  39. van Deuren M., van der Ven-Jongekrijg J., Demacker P. N., Bartelink A. K., van Dalen R., Sauerwein R. W., Gallati H., Vannice J. L., van der Meer J. W. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis. 1994 Jan;169(1):157–161. doi: 10.1093/infdis/169.1.157. [DOI] [PubMed] [Google Scholar]
  40. von der Möhlen M. A., Kimmings A. N., Wedel N. I., Mevissen M. L., Jansen J., Friedmann N., Lorenz T. J., Nelson B. J., White M. L., Bauer R. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 1995 Jul;172(1):144–151. doi: 10.1093/infdis/172.1.144. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES